The “Beta-thalassemia (B-thal) – Pipeline Insight, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Beta-thalassemia (B-thal) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Beta-thalassemia (B-thal) market.
A detailed picture of the Beta-thalassemia (B-thal) pipeline landscape is provided, which includes the disease overview and Beta-thalassemia (B-thal) treatment guidelines. The assessment part of the report embraces in-depth Beta-thalassemia (B-thal) commercial assessment and clinical assessment of the Beta-thalassemia (B-thal) pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Beta-thalassemia (B-thal) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Beta-thalassemia (B-thal) with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Beta-thalassemia (B-thal) treatment.
- Beta-thalassemia (B-thal) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Beta-thalassemia (B-thal) market.
Scope of the Report
- The Beta-thalassemia (B-thal) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Beta-thalassemia (B-thal) across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Beta-thalassemia (B-thal) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Beta-thalassemia (B-thal) research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Beta-thalassemia (B-thal).
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Yahoo